Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer/ Metastatic Breast Cancer
Interventions: DRUG: Abemaciclib
Sponsor: Technical University of Munich
Collaborators: Eli Lilly and Company